Asarina Pharma completed a financing round raising €7M (US$7.7M) from new and existing investors
Biohaven Pharmaceutical Holding Co. Ltd. (subsidiary of Portage Biotech Inc.)
New Haven, Conn.
Biohaven completed an $80M round led by Venrock and joined by RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, John W. Childs, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Greg Bailey and Litmore Capital; two undisclosed blue chip pharmaceutical companies also participated
Bonesupport raised $37M in private equity and debt in a financing led by Tellacaq AB, with existing shareholders Healthcap, Lundbeckfond Ventures, Industridonden and the Swedish national pension fund AP3 participating
Cornerstone Pharmaceuticals Inc.
Cornerstone received a $10M investment for a minority interest from IDT Corp., of Newark, N.J.
Curevac added $29.5M in new funds from German investors, including Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte, and the regional state-owned bank Landeskreditbank Baden-Württemberg, which contributed €11.M (US$12.M), as well as earlier investors
Enterprise Therapeutics Ltd.
Enterprise Therapeutics closed a £4M (US$5M) financing led by existing investors Epidarex Capital and Imperial Innovations
Galera Therapeutics Inc.
Galera raised $15M in funding from new investor Sofinnova Ventures, which brings its series B round total to $57M
Glycomine raised $12M in a series A financing led by Sanderling Ventures and supported by Chiesi Ventures as well as existing high net worth individuals and patients
Innovent Biologics Inc.
Innovent raised $260M in a series D round led by a Future Industry Investment Fund, and including China Life Private Equity Ltd., Milestone, Ping An and Taikang Insurance Group; existing international investors, Legend Capital, Temasek and Hillhouse Capital also participated
Magenta raised $48.5M in a series A round led by Third Rock Ventures LLC and Atlas Venture, and joined by GV, Access Industries and Partners Innovation Fund
Novo Seeds and Almi Invest are investing up to SEK6.3M (US$688,190) in Merozyne dependent on pre-agreed milestones
NBE Therapeutics AG
NBE Therapeutics closed a CHF20M (US$20.5M) series B round, led by PPF Group, with participation from Boehringer Ingelheim Venture Fund, all other existing private investors and a new private investor
Nohla Therapeutics Inc.
Nohla raised $43.5M in a series A round led by Arch Venture Partners, and including participation from 5AM Ventures and existing investor, the Jagen Group
Oxthera agreed on a €32M (US$34M) round co-led by Life Sciences Partners, Ysios Capital, Sunstone Capital and Flerie Invest, in addition to Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet
St. Paul, Minn.
Recombinetics completed an $11M round
Recursion Pharmaceuticals Inc.
Salt Lake City
Recursion Pharmaceuticals closed an additional $2.15M in funding, bringing its series A round to a total of $15.05M; investors were individuals and Felicis Ventures, joining Lux Capital, with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Wild Basin Investments and several prominent angel investors
Syntimmune said the final $8M tranche of its $26M series A financing was triggered by dose selection for SYNT001; $10M was raised in March
T3 Pharmaceuticals Ltd.
T3 Pharmaceuticals closed its first financing round provided by private Swiss investors
Tetra Discovery Partners Inc.
Grand Rapids, Mich.
Tetra Discovery Partners closed a $5M series A venture financing co-led by the Apjohn Group and Grand Angels, with participation of previous investors, as well as Dolby Family Ventures, the Alzheimer's Drug Discovery Foundation and other private investors; with conversion of two debt rounds, the total series A financing rolls up to about $7.2M
Themis Bioscience GmbH
Themis closed a €10M (US$10.6M) series B financing round, which included participation from the company's existing investors Ventech, Omnes Capital and Wellington Partners, with the latter leading the round
Turnstone Biologics Inc.
Turnstone Biologics raised $41.1M in a series B round led by Orbimed and F-Prime Capital Partners; Facit also participated alongside Versant
Zucara Therapeutics Inc.
Vancouver, British Columbia
Zucara Therapeutics received a C$525,000 (US$391,866) investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development and MaRS Innovation
Currency conversions are based on exchange rates at the time of the deal.
The date indicated refers to the BioWorld Today issue in which the news item can be found.
This chart includes only biotech companies that develop therapeutics.
ND = Not disclosed.